Show simple item record

dc.contributor.authorLassila, Riitta
dc.contributor.authorHolme, Pål André
dc.contributor.authorLandorph, Andrea
dc.contributor.authorPetrini, Pia
dc.contributor.authorOnundarson, Páll T
dc.contributor.authorHillarp, Andreas
dc.date.accessioned2012-06-04T11:21:20Z
dc.date.available2012-06-04T11:21:20Z
dc.date.issued2011-07
dc.date.submitted2012-06-04
dc.identifier.citationSemin. Thromb. Hemost. 2011, 37(5):495-502 Semin. Thromb. Hemost.en_GB
dc.identifier.issn1098-9064
dc.identifier.pmid22102192
dc.identifier.doi10.1055/s-0031-1281034
dc.identifier.urihttp://hdl.handle.net/2336/227415
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.en_GB
dc.description.abstractVon Willebrand disease (VWD) is the most common inherited bleeding disorder characterized by spontaneous or tissue injury-related, mostly mucocutaneous, bleeding events. VWD affects both males and females and is caused by quantitative or qualitative deficiency of Von Willebrand factor. The diagnostic procedure is complicated because VWD is highly heterogeneous, and differential diagnosis from platelet disorders may be challenging. Moreover, these defects may even coexist, impacting the bleeding phenotype. Mild and moderate VWD can be difficult to distinguish from the normal population, and VWD subtyping may also be problematic. This article summarizes the guidelines of the Nordic Haemophilia Council (NHC), which are intended to serve as a practical tool and provide the standards for diagnosing and treating VWD patients. The complete Nordic Guidelines on VWD are available at the NHC Web site (http://nordhemophilia.org).
dc.description.sponsorshipCSL Behringen_GB
dc.language.isoenen
dc.publisherThiemeen_GB
dc.relation.urlhttp://dx.doi.org/10.1055/s-0031-1281034en_GB
dc.rightsArchived with thanks to Seminars in thrombosis and hemostasisen_GB
dc.subject.meshDenmarken_GB
dc.subject.meshFinlanden_GB
dc.subject.meshGeographyen_GB
dc.subject.meshHemophilia Aen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIcelanden_GB
dc.subject.meshNorwayen_GB
dc.subject.meshPractice Guidelines as Topicen_GB
dc.subject.meshSwedenen_GB
dc.subject.meshvon Willebrand Diseasesen_GB
dc.titleNordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease.en
dc.typeArticleen
dc.contributor.departmentUnit of Coagulation Disorders, Department of Hematology and Clinical Chemistry Laboratory Services, Helsinki University Central Hospital, Helsinki, Finland. riitta.lassila@hus.fien_GB
dc.identifier.journalSeminars in thrombosis and hemostasisen_GB
html.description.abstractVon Willebrand disease (VWD) is the most common inherited bleeding disorder characterized by spontaneous or tissue injury-related, mostly mucocutaneous, bleeding events. VWD affects both males and females and is caused by quantitative or qualitative deficiency of Von Willebrand factor. The diagnostic procedure is complicated because VWD is highly heterogeneous, and differential diagnosis from platelet disorders may be challenging. Moreover, these defects may even coexist, impacting the bleeding phenotype. Mild and moderate VWD can be difficult to distinguish from the normal population, and VWD subtyping may also be problematic. This article summarizes the guidelines of the Nordic Haemophilia Council (NHC), which are intended to serve as a practical tool and provide the standards for diagnosing and treating VWD patients. The complete Nordic Guidelines on VWD are available at the NHC Web site (http://nordhemophilia.org).


This item appears in the following Collection(s)

Show simple item record